Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
Suboptimal responses to a primary vaccination course have been reported in the elderly, but there is little information regarding the impact of age on responses to booster third doses. Here, we show that individuals 70 years or older (median age 73, range 70-75) who received a primary two-dose schedule with AZD1222 and booster third dose with mRNA vaccine achieve significantly lower neutralizing antibody responses against SARS-CoV-2 spike pseudotyped virus compared with those younger than 70 (median age 66, range 54-69) at 1 month post booster. Impaired neutralization potency and breadth post third dose in the elderly is associated with circulating "atypical" spike-specific B cells expressing CD11c and FCRL5. However, when considering individuals who received three doses of mRNA vaccine, we did not observe differences in neutralization or enrichment in atypical B cells. This work highlights the finding that AdV and mRNA COVID-19 vaccine formats differentially instruct the memory B cell response.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Cell reports - 42(2023), 8 vom: 29. Aug., Seite 112991 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
AZD1222 |
|---|
| Anmerkungen: |
Date Completed 04.09.2023 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2023.112991 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36089304X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36089304X | ||
| 003 | DE-627 | ||
| 005 | 20240313233553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2023.112991 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM36089304X | ||
| 035 | |a (NLM)37590132 | ||
| 035 | |a (PII)S2211-1247(23)01002-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferreira, Isabella A T M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.09.2023 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Suboptimal responses to a primary vaccination course have been reported in the elderly, but there is little information regarding the impact of age on responses to booster third doses. Here, we show that individuals 70 years or older (median age 73, range 70-75) who received a primary two-dose schedule with AZD1222 and booster third dose with mRNA vaccine achieve significantly lower neutralizing antibody responses against SARS-CoV-2 spike pseudotyped virus compared with those younger than 70 (median age 66, range 54-69) at 1 month post booster. Impaired neutralization potency and breadth post third dose in the elderly is associated with circulating "atypical" spike-specific B cells expressing CD11c and FCRL5. However, when considering individuals who received three doses of mRNA vaccine, we did not observe differences in neutralization or enrichment in atypical B cells. This work highlights the finding that AdV and mRNA COVID-19 vaccine formats differentially instruct the memory B cell response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AZD1222 | |
| 650 | 4 | |a BNT162b2 | |
| 650 | 4 | |a CP: Immunology | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a elderly | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 700 | 1 | |a Lee, Colin Y C |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, William S |e verfasserin |4 aut | |
| 700 | 1 | |a Abdullahi, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Dratva, Lisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Tuong, Zewen Kelvin |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Benjamin J |e verfasserin |4 aut | |
| 700 | 1 | |a Ferdinand, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Guillaume, Stephane M |e verfasserin |4 aut | |
| 700 | 1 | |a Potts, Martin O P |e verfasserin |4 aut | |
| 700 | 1 | |a Perera, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Krishna, Benjamin A |e verfasserin |4 aut | |
| 700 | 1 | |a Peñalver, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Cabantous, Mia |e verfasserin |4 aut | |
| 700 | 1 | |a Kemp, Steven A |e verfasserin |4 aut | |
| 700 | 1 | |a Ceron-Gutierrez, Lourdes |e verfasserin |4 aut | |
| 700 | 1 | |a Ebrahimi, Soraya |e verfasserin |4 aut | |
| 700 | 0 | |a CITIID-NIHR BioResource COVID-19 Collaboration |e verfasserin |4 aut | |
| 700 | 1 | |a Lyons, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Kenneth G C |e verfasserin |4 aut | |
| 700 | 1 | |a Bradley, John |e verfasserin |4 aut | |
| 700 | 1 | |a Collier, Dami A |e verfasserin |4 aut | |
| 700 | 1 | |a McCoy, Laura E |e verfasserin |4 aut | |
| 700 | 1 | |a van der Klaauw, Agatha |e verfasserin |4 aut | |
| 700 | 1 | |a Thaventhiran, James E D |e verfasserin |4 aut | |
| 700 | 1 | |a Farooqi, I Sadaf |e verfasserin |4 aut | |
| 700 | 1 | |a Teichmann, Sarah A |e verfasserin |4 aut | |
| 700 | 1 | |a MacAry, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Doffinger, Rainer |e verfasserin |4 aut | |
| 700 | 1 | |a Wills, Mark R |e verfasserin |4 aut | |
| 700 | 1 | |a Linterman, Michelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Clatworthy, Menna R |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ravindra K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 42(2023), 8 vom: 29. Aug., Seite 112991 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:8 |g day:29 |g month:08 |g pages:112991 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2023.112991 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 8 |b 29 |c 08 |h 112991 | ||